Efficacy and safety of aripiprazole a 12 weeks, multi-center, open-label switching to aripiprazole study in stable outpatients with schizophrenia or schizoaffective disorder

被引：0
|
作者：
Kim, C. [1 ]
Chung, S. [1 ]
Lee, J. [1 ]
Kwon, J. [1 ]
Lee, Y. [1 ]
Kim, C. [1 ]
Oh, K. [1 ]
Jeon, Y. [1 ]
Ham, B. [1 ]
Kim, D. [1 ]
Jung, H. [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
SCHIZOPHRENIA BULLETIN | 2007年 / 33卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：437 / 437
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of aripiprazole in outpatients with schizophrenia or schizoaffective disorder
    Shin, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S515 - S515
  • [2] Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol
    de Oliveira, Irismar Reis
    Elkis, Helio
    Gattaz, Wagner Farid
    Chaves, Ana Cristina
    de Sena, Eduardo Ponde
    de Matos e Souza, Fabio Gomes
    Campos, Joao Alberto
    Bueno, Joao Romildo
    Costa e Silva, Jorge Alberto
    Louza, Mario Rodrigues
    de Abreu, Paulo Belmonte
    CNS SPECTRUMS, 2009, 14 (02) : 93 - 102
  • [3] A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder
    Kim, Chang Yoon
    Chung, Seockhoon
    Lee, Joon-Noh
    Kwon, Jun Soo
    Kim, Do Hoon
    Kim, Chul Eung
    Jeong, Bumseok
    Jeon, Yang-Whan
    Lee, Min-Soo
    Jun, Tae-Youn
    Jung, Hee-Yeon
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (04) : 181 - 188
  • [4] Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
    Ryckmans, V.
    Kahn, J. P.
    Modell, S.
    Werner, C.
    McQuade, R. D.
    Kerselaers, W.
    Lissens, J.
    Sanchez, R.
    PHARMACOPSYCHIATRY, 2009, 42 (03) : 114 - 121
  • [5] Comparison of perospirone and aripiprazole: a 12 weeks, randomised, open-label study in Japanese schizophrenia patients
    Takekita, Y.
    Kato, M.
    Sakai, S.
    Suwa, A.
    Okugawa, G.
    Kinoshita, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S481 - S482
  • [6] Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
    Habibi, N.
    Dodangi, N.
    Efficacy, Nazeri A.
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2015, 40 (06) : 548 - 549
  • [7] The efficacy and safety of aripiprazole combination with divalproex in patients with acute manic and mixed episode: A multi-center, prospective, open-label study (The SMART study)
    Bahk, W. -M.
    Woo, Y. S.
    Chung, M. Y.
    Kim, D. -H.
    Yoon, B. -H.
    Lee, J. H.
    Ahn, Y. M.
    Chung, S. -K.
    Kim, J. -G.
    Lee, K. H.
    Paik, K. -C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 123 - 123
  • [8] An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder
    Findling, Robert L.
    McNamara, Nora K.
    Youngstrom, Eric A.
    Stansbrey, Robert J.
    Frazier, Thomas W.
    Lingler, Jacqui
    Otto, Benjamin D.
    Demeter, Christine A.
    Rowles, Brieana M.
    Calabrese, Joseph R.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (04) : 345 - 351
  • [9] Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole
    Obayashi, Yoshiaki
    Mitsui, Satoshi
    Sakamoto, Shinji
    Minao, Nozomu
    Yoshimura, Bunta
    Kono, Toshiki
    Yada, Yuji
    Okahisa, Yuko
    Takao, Soshi
    Kishi, Yoshiki
    Takeda, Toshihiko
    Takaki, Manabu
    Yamada, Norihito
    PSYCHOPHARMACOLOGY, 2020, 237 (01) : 167 - 175
  • [10] Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole
    Yoshiaki Obayashi
    Satoshi Mitsui
    Shinji Sakamoto
    Nozomu Minao
    Bunta Yoshimura
    Toshiki Kono
    Yuji Yada
    Yuko Okahisa
    Soshi Takao
    Yoshiki Kishi
    Toshihiko Takeda
    Manabu Takaki
    Norihito Yamada
    Psychopharmacology, 2020, 237 : 167 - 175
12345